RecruitingPhase 3NCT06544499
A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
Studying Autoimmune thrombocytopenia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- argenx
- Intervention
- Efgartigimod IV(biological)
- Enrollment
- 69 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2028
Study locations (30)
- Mayo Clinic Hospital Scottsdale, Phoenix, Arizona, United States
- University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, United States
- Sharp Memorial Hospital, Oceanside, California, United States
- University of Colorado Hospital, Aurora, Colorado, United States
- Yale University School of Medicine, New Haven, Connecticut, United States
- Georgetown University Hospital, Washington D.C., District of Columbia, United States
- The University of Chicago Medicine, Chicago, Illinois, United States
- The University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States
- Tulane University, New Orleans, Louisiana, United States
- Henry Ford Health, Detroit, Michigan, United States
- University of Minnesota, Minneapolis, Minnesota, United States
- Regional Cancer Care Associates, LLC (RCCA), Little Silver, New Jersey, United States
- Clinical Research Alliance Inc., Westbury, New York, United States
- Duke University Medical Center, Durham, North Carolina, United States
- Brody School of Medicine at East Carolina University, Greenville, North Carolina, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06544499 on ClinicalTrials.govOther trials for Autoimmune thrombocytopenia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07559331High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune ThrombocytopeniaShandong University
- RECRUITINGPHASE2NCT07362238Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07362199Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGEARLY PHASE1NCT07441525UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological DiseasesUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGPHASE2NCT07234019Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07297563Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07294365A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11)Dizal Pharmaceuticals
- RECRUITINGPHASE2NCT07104565Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell DisordersIncyte Corporation